{"id":1439,"date":"2020-11-24T14:30:00","date_gmt":"2020-11-24T14:30:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-ab-programmet-for-oncopeptides-virtuella-kapitalmarknadsdag-den-30-november-ar-publicerat\/"},"modified":"2026-02-23T13:18:16","modified_gmt":"2026-02-23T13:18:16","slug":"oncopeptides-ab-programmet-for-oncopeptides-virtuella-kapitalmarknadsdag-den-30-november-ar-publicerat","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-programmet-for-oncopeptides-virtuella-kapitalmarknadsdag-den-30-november-ar-publicerat\/","title":{"rendered":"Oncopeptides AB: Programmet f\u00f6r Oncopeptides virtuella kapitalmarknadsdag den 30 november \u00e4r publicerat"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">STOCKHOLM &#8211; 24 november 2020 &#8211; Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), ett l&auml;kemedelsf&ouml;retag fokuserat p&aring; utvecklingen av riktade terapier f&ouml;r sv&aring;rbehandlade hematologiska sjukdomar meddelade idag att f&ouml;retaget har f&auml;rdigst&auml;llt programmet f&ouml;r den kommande virtuella kapitalmarknadsdagen f&ouml;r investerare, analytiker och journalister den 30 november 2020. Programmet finns tillg&auml;ngligt p&aring; f&ouml;retagets hemsida www.oncopeptides.com\/se\/kalender\/<\/p>\n<p><\/strong><\/div>\n<p class=\"mfn-wp-retain\">Kapitalmarknadsdagen kommer att s&auml;ndas live och webcasten kommer att finnas tillg&auml;nglig under: <a href=\"https:\/\/tv.streamfabriken.com\/oncopeptides-cmd-2020\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/tv.streamfabriken.com\/oncopeptides-cmd-2020<\/a>.<\/p>\n<p class=\"mfn-wp-retain\">Presentationerna fr&aring;n kapitalmarknadsdagen kommer att l&auml;ggas upp p&aring; f&ouml;retagets hemsida i anslutning till m&ouml;tet.<\/p>\n<p class=\"mfn-wp-retain\">Oncopeptides Virtuella kaptitalmarknadsdag<br \/>14.00 &#8211; 16.00 CET (8:00am-10am EST) 30 november 2020<\/p>\n<p class=\"mfn-wp-retain\">&#8221;Building a Fully Integrated Biotechnology Company&#8221;<\/p>\n<p class=\"mfn-wp-retain\">Introduction and Strategy for Value Growth &#8211; Marty J Duvall, CEO Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">Multiple Myeloma<\/p>\n<p class=\"mfn-wp-retain\">&#8221;Myeloma remains one of the largest unmet medical needs within hematology&#8221;&nbsp;<\/p>\n<ul>\n<li>Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York<\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\">Relapsed refractory multiple myeloma and melflufen &#8211; clinical experience with melflufen<\/p>\n<p class=\"mfn-wp-retain\">Panel discussion<\/p>\n<ul>\n<li>Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston<\/li>\n<li>Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca<\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\">Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">The clinical development program for melflufen<\/p>\n<p class=\"mfn-wp-retain\">&#8221;Understanding how melflufen can help patients the most&#8221; &#8211; Jakob Lindberg, CSO Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">Successfully making the drug available for patients in the US<\/p>\n<p class=\"mfn-wp-retain\">Overview of US launch of melflufen &#8211; Marty J Duvall, CEO Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">Questions and Answers<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information kontakta:<br \/>Rein Piir, Head of Investor Relations, Oncopeptides<br \/>Mejl: rein.piir@oncopeptides.com&nbsp;<br \/>Mobil: +46 70 853 72 92<\/p>\n<p class=\"mfn-wp-retain\">Informationen l&auml;mnades f&ouml;r offentligg&ouml;rande den 24 november kl. 15.30 (CET).<\/p>\n<p class=\"mfn-wp-retain\">Om Oncopeptides<br \/>Oncopeptides &auml;r ett l&auml;kemedelsf&ouml;retag fokuserat p&aring; utvecklingen av riktade terapier f&ouml;r sv&aring;rbehandlade hematologiska sjukdomar. Den ledande produktkandidaten melflufen &auml;r f&ouml;rst i en ny klass av peptidl&auml;nkade l&auml;kemedel som riktas mot aminopeptidaser och snabbt fris&auml;tter alkylerande cellgifter inne i tum&ouml;rceller. Melflufen utvecklas som en ny behandling av den hematologiska cancersjukdomen multipelt myelom och utv&auml;rderas i ett flertal kliniska studier inklusive den registreringsgrundande fas 2-studien HORIZON och den p&aring;g&aring;ende fas 3-studien OCEAN. Baserat p&aring; resultaten fr&aring;n HORIZON-studien har en ans&ouml;kan om villkorat marknadsgodk&auml;nnande f&ouml;r melflufen i kombination med dexametason l&auml;mnats in till den amerikanska l&auml;kemedelsmyndigheten FDA, f&ouml;r behandling av vuxna patienter med trippelklassrefrakt&auml;rt multipelt myelom. FDA har beviljat bolagets ans&ouml;kan en prioriterad granskning och fastst&auml;llt ett PDUFA-datum, dvs. n&auml;r granskningen ska vara klar, till den 28 februari 2021. Oncopeptides globala huvudkontor ligger i Stockholm och huvudkontoret f&ouml;r den amerikanska verksamheten &aring;terfinns i Boston, Massachusetts. Bolaget &auml;r noterat i Mid Cap-segmentet p&aring; Nasdaq Stockholm med kortnamnet ONCO. Mer information finns tillg&auml;nglig p&aring; &nbsp;www.oncopeptides.com.<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3242722%2F1339294.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3242722%2F1339294.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>STOCKHOLM &#8211; 24 november 2020 &#8211; Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), ett l&auml;kemedelsf&ouml;retag fokuserat p&aring; utvecklingen av riktade terapier f&ouml;r sv&aring;rbehandlade hematologiska sjukdomar meddelade idag att f&ouml;retaget har f&auml;rdigst&auml;llt programmet f&ouml;r den kommande virtuella kapitalmarknadsdagen f&ouml;r investerare, analytiker och journalister den 30 november 2020. Programmet finns tillg&auml;ngligt p&aring; f&ouml;retagets hemsida www.oncopeptides.com\/se\/kalender\/ Kapitalmarknadsdagen kommer att [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[392,391,393],"class_list":["post-1439","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-ir","mfn-news-tag-news","mfn-news-tag-swedish"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1439"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1439"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}